Obesity Series Live

CME Presentations

Pharmacotherapy of Obesity


Presentations

  • CME
    1.0

    Pharmacotherapy of Obesity: Practical Applications for Clinical Care

    Speakers:Caroline Apovian, MD, FACP, FACN, Professor of Medicine and Pediatrics
    Kimberly Gudzune, MD, MPH, Assistant Professor of Medicine
    Scott Kahan, MD, MPH, FTOS, DABOM, Medical Director

    Duration: 60 minutes

    Presented on: June 7, 2017


Speakers

  • Caroline Apovian, MD, FACP, FACN

    Caroline Apovian, MD, FACP, FACN

    Caroline Apovian, MD, FACP, FACN

    Professor of Medicine and Pediatrics

    Caroline M. Apovian, MD, FACP, DABOM, is a professor of medicine and pediatrics in the Section of Endocrinology, Diabetes, and Nutrition at Boston University School of Medicine, and is the director of the Center for Nutrition and Weight Management at Boston Medical Center. Dr Apovian’s current research interests include weight loss and its effects on endothelial cell function, obesity and cardiovascular disease, adipose cell metabolism and inflammation, resolution of diabetes and cardiovascular disease in the bariatric surgery population, disparities in the treatment of obesity in underserved populations and novel pharmacotherapeutic anti-obesity agents. She has given over 150 invited lectures nationally and internationally, and currently serves as President Elect of The Obesity Society.
  • Kimberly Gudzune, MD, MPH

    Kimberly Gudzune, MD, MPH

    Kimberly Gudzune, MD, MPH

    Assistant Professor of Medicine

    Kimberly A. Gudzune, MD MPH, is assistant professor at the Johns Hopkins University School of Medicine and practices as an obesity medicine specialist at the Johns Hopkins Digestive Weight Loss Center in Baltimore, Maryland. She earned her medical and master of public health degrees from Tulane University in New Orleans, Louisiana. Dr Gudzune’s research focuses on how patient obesity influences the health care experience, efficacy of commercial weight-loss programs, and how features of the built and social environment influence diet and exercise habits among low-income urban populations. Her research has won many awards and has been featured by The New York Times and National Public Radio. She is board-certified in internal medicine and a diplomat of the American Board of Obesity Medicine.
  • Scott Kahan, MD, MPH, FTOS, DABOM

    Scott Kahan, MD, MPH, FTOS, DABOM

    Scott Kahan, MD, MPH, FTOS, DABOM

    Medical Director

    Scott Kahan, MD, MPH, is medical director of the Strategies To Overcome and Prevent (STOP) Obesity Alliance, chair of the Clinical Committee for The Obesity Society, and director of the National Center for Weight and Wellness. His clinical practice and research addresses obesity prevention and treatment, chronic disease risk reduction, health behavior change in populations, and clinical aspects of weight management. His public policy work focuses on expanding access to care for obesity treatment services, addressing weight stigma, and training physicians in obesity treatment modalities. He is faculty at the Johns Hopkins Bloomberg School of Public Health, the George Washington University School of Public Health and Health Services, and the George Washington University School of Medicine.

CME Information

Pharmacotherapy of Obesity: Practical Applications for Clinical Care

 
    

Presented by Boston University School of Medicine in collaboration with PlatformQ Health Education, LLC and The Obesity Society

ACKNOWLEDGEMENT This activity is supported by an educational grant from Novo Nordisk.

TUITION Complimentary

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and PlatformQ Health Education, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Activity Boston University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PROGRAM OVERVIEW Obesity has been acknowledged as a global health crisis. In the United States, recent national estimates suggest that 36% of adults and 17% of youths meet national criteria to be classified as obese. Obesity impacts many other medical conditions including diabetes, cardiovascular disease, and orthopedic issues. The need for health care professionals to slow the epidemic of obesity has long been a significant clinical challenge. Many health care providers ascribe the inability to lose weight to a lack of patient adherence to weight management therapies, particularly lifestyle change. Yet, there are many complex factors impacting the inability to reverse obesity beyond simple adherence issues that are difficult to recognize, much less address clinically. The critical first step is accepting that obesity is a disease, not a behavior. Clinicians must then be prepared to learn and utilize different approaches to this long-standing clinical challenge. Currently, only one-third of obese patients ever receive an obesity diagnosis and fewer than one-quarter receive counseling on diet, weight reduction, or exercise. A survey of US primary care providers revealed that physicians treating these patients have little confidence in their ability to manage obesity. In 2013, the American Medical Association published a policy stating that obesity was a disease and thus required a range of medical interventions to advance treatment and prevention. Major medical societies have recently issued guidelines for obesity management with an expanded emphasis on a number of treatments, particularly pharmacologic and surgical, to address the suboptimal clinical management of obese patients. Pharmacotherapy for obesity is an important tool when properly used by trained providers based on scientific evidence, established indications and guidelines for titration and therapeutic outcomes assessment. The goal of this program is to identify obesity as a disease and prepare health care providers to use available pharmacological treatment options to treat obesity when lifestyle interventions are deemed to be insufficient. With the recent advances in pharmacologic treatments for obesity, clinicians require current information regarding their modes of action, efficacy and safety profiles and guidance in choosing among available medications.

TARGET AUDIENCE The intended audience for this activity consists of health care providers of people who may be obese and need pharmacotherapeutic interventions and includes the following groups:

  • Providers: Physicians (primary care and those of relevant specialties such as endocrinology or cardiology), nurse practitioners, physician assistants
  • Lifestyle specialists: Mental health providers, dietitians/nutritionists, exercise professionals

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Identify obesity as a disease, not a behavioral problem, and consider the implications of that paradigm shift on attitudes toward treating the condition
Identify indications that lifestyle interventions have not been sufficient to result in weight loss
Describe the pharmacology of, and indications for, the use of the currently available medications for chronic weight management
Describe ongoing management of people using anti-obesity medications, including means to gauge both therapeutic efficacy or the need to consider bariatric surgery
 

DATE OF RELEASE/EXPIRATION Live Internet Activity Wednesday, June 7, 2017, from 12:00 PM EST – 1:00 PM EST Enduring Material The enduring material will be available from June 7, 2017 – December 7, 2017

ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.

FACULTY Caroline M. Apovian, MD, FACP, DABOM (Course Director) Director, Center for Nutrition and Weight Management, Boston Medical Center Professor of Medicine and Pediatrics, Section of Endocrinology, Diabetes, and Nutrition Boston University School of Medicine Boston, Massachusetts Scott Kahan, MD, MPH Director, National Center for Weight Loss and Wellness Washington, DC Kimberly A. Gudzune, MD, MPH Assistant Professor Johns Hopkins University School of Medicine Baltimore, Maryland CME Course Advisor: Amanda Velazquez, MD Nutrition and Obesity Medicine Fellow Endocrinology, Diabetes and Nutrition Boston Medical Center Boston, Massachusetts

DISCLOSURE POLICY Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

FINANCIAL DISCLOSURES

Presenters Disclosures
Caroline M. Apovian, MD, FACP, DABOM (Course Director)

Consultant: Merck; Nutrisystem; Zafgen; sanofi-aventis; Orexigen; EnteroMedics; Scientific Intake; Gelesis; Ferring; Takeda; Novo Nordisk Research funding: Aspire Bariatrics; GI Dynamics; Pfizer; Gelesis; Orexigen; MetaProteomics; Takeda; MYOS Corporation; The Dr. Robert C. and Veronica Atkins Foundation Stockholder: Science Smart, LLC

Scott Kahan, MD, MPH

Consultant: Novo Nordisk; Takeda; Orexigen; Eisiai

Kimberly A. Gudzune, MD, MPHKimberly A. Gudzune, MD, MPH

Has no relevant financial relationships to disclose.

Boston University School of Medicine Peer Reviewer Disclosures
Amanda Velazquez, MD Has no relevant financial relationships to disclose.
Boston University School of Medicine Program Managers Disclosures
Elizabeth Drury Has no relevant financial relationships to disclose.
Boston University School of Medicine Program Managers Disclosures
Elizabeth Drury Has no relevant financial relationships to disclose.
PlatformQ Health Education, LLC Disclosures
Agnes Yang, MD, Medical Director Has no relevant financial relationships to disclose.
Karen Greb-Murphy, Program Manager Has no relevant financial relationships to disclose.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLAIMERS (if applicable): ALL PROGRAMS, ACTIVITIES, AND MATERIALS PROVIDED BY BOSTON UNIVERSITY OFFICE OF CONTINUING MEDICAL EDUCATION OR ITS ASSOCIATES ARE PROVIDED ON THE CONDITION THAT THEY BE USED SOLELY FOR EDUCATIONAL PURPOSES BY QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE CONTINUING MEDICAL EDUCATION PROGRAMS, ACTIVITIES OR MATERIALS. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Boston University School of Medicine, ObesitySeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION: Please send CME inquiries to: cme@bu.edu For issues with your CME Certificate, Please contact ObesitySeriesLive at 977–394–1306 or at Support@ObesitySeriesLive.com